# Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus

> **NCT01405196** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 183 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **BIOLOGICAL:** PF-04236921
- **BIOLOGICAL:** PF-04236921
- **BIOLOGICAL:** PF-04236921
- **BIOLOGICAL:** PF-04236921

## Key facts

- **NCT ID:** NCT01405196
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2017-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01405196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01405196, "Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01405196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*